术前新辅助放化疗对T3、T4期低位直肠癌患者疗效及复发的影响  

Effect of Preoperative Neoadjuvant Chemoradiotherapy on Efficacy of Recurrence of Stage-T3,T4 Low Rectal Cancer

作　　者：杨超[1] 王悦冬[1] 李国强[1] 黎佳全[1] 

机构地区：[1]梅州市人民医院,广东梅州514031

出　　处：《深圳中西医结合杂志》2017年第7期5-7,共3页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:探讨术前新辅助放化疗对T3、T4期低位直肠癌患者疗效及复发的影响。方法:将2010年2月至2012年2月梅州市人民医院收治的低位直肠癌患者90例随机分为两组,各45例。两组均采用全直肠系膜切除术(TME)联合新辅助放化疗,其中对照组术后放化疗,而观察组术前放化疗,比较两组手术疗效、术后1年、3年生存率、复发率及并发症发生率。结果:观察组手术总有效率、术后1年、3年生存率均明显高于对照组,复发率与并发症发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:T3、T4期低位直肠癌患者行术前新辅助放化疗,可显著改善手术疗效,预防复发,延长生存期。Objective To investigate the effect of preoperative neoadjuvant chemoradiotherapy on efficacy of recurrence of stage-T3, T4 low rectal cancer. Methods 90 patients with low rectal cancer in our hospital from February 2010 to February 2012 were randomly divided into two groups, 45 cases in each. Two groups took total mesorectal excision(TME) combined with neoadjuvant chemoradiotherapy, control group took postoperative chemoradiotherapy and observation group took preoperative chemoradiotherapy. The surgical efficacy, survival rate after surgery for 1 year and 3 years, recurrence rate and incidence of complications of two groups were compared. Results The total surgical effective rate, survival rate after surgery for 1 year and 3 years of observation group were significantly higher than those of control group, the recurrence rate and the incidence of complications were significantly lower than control group(P<0.05). Conclusion Neoadjuvant chemoradiotherapy for stage-T3, T4 low rectal cancer can significantly improve surgical efficacy, prevent recurrence and prolong survival period, which is worthy of promotion.

关 键 词：新辅助放化疗 低位直肠癌 全直肠系膜切除术 

分 类 号：R735.37[医药卫生—肿瘤]